Advertisement

Drug-Induced Oral Complications

  • Kentaro Ikeda
    Correspondence
    Department of Diagnostics and Biological Sciences, University of Colorado School of Dental Medicine, 13065 East 17th Avenue, Mail Stop F844, Aurora, CO 80045.
    Affiliations
    Department of Diagnostics and Biological Sciences, University of Colorado School of Dental Medicine, 13065 East 17th Avenue, Mail Stop F844, Aurora, CO 80045, USA

    Department of Family Medicine, University of Colorado School of Medicine, 12631 East 17th Avenue, Aurora, CO 80045, USA
    Search for articles by this author
      Because of an aging population and rapid development of new medications, dentistry and medicine will likely face a significant increase in patients with drug related reactions.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      References

        • Ortman J.M.
        • Velkoff V.A.
        • Hogan H.
        An aging nation: the older population in the United States, current population reports, P25–1140.
        U.S. Census Bureau, Washington, DC2014 (Available at:)
        • Al-Khudari S.
        • Loochtan M.J.
        • Peterson E.
        • et al.
        Management of angiotensin-converting enzyme inhibitor-induced angioedema.
        Laryngoscope. 2011; 121: 2327-2334
        • Neville B.W.
        • Damm D.D.
        • Allen C.M.
        • et al.
        Oral and maxillofacial pathology.
        4th edition. Elsevier, St Louis (MO)2015
        • Nguyen V.
        • Simon L.
        • Jaqua E.
        Allergic dermatoses.
        Prim Care Clin Off Pract. 2016; 43: 433-449
        • Sanchez-Borges M.
        • Capriles-Hulett A.
        • Caballero-Fonseca F.
        NSAID-induced urticaria and angioedema: a reappraisal of its clinical management.
        Am J Clin Dermatol. 2002; 3: 599-607
        • Kaplan A.
        • Greaves M.
        Angioedema.
        J Am Acad Dermatol. 2005; 53: 373-388
        • Mahmoudpour S.H.
        • Baranova E.V.
        • Souverein P.C.
        • et al.
        • PREDICTION-ADR consortium
        Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK clinical practice research datalink.
        Br J Clin Pharmacol. 2016; 82: 1647-1659
        • Zuraw B.
        Hereditary angioedema.
        N Engl J Med. 2008; 359: 1027-1036
        • Scalese M.J.
        • Reinaker T.S.
        Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors.
        Am J Health Syst Pharm. 2016; 73: 873-879
        • Bova M.
        • Guilarte M.
        • Sala-Cunill A.
        • et al.
        Treatment of ACEI-related angioedema with icatibant: a case series.
        Intern Emerg Med. 2015; 10: 345-350
        • Celentano A.
        • Tovaru S.
        • Yap T.
        • et al.
        Oral erythema multiforme: trends and clinical findings of a large retrospective European case series.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120: 707-716
        • Shah S.N.
        • Chauhan G.R.
        • Manjunatha B.S.
        • et al.
        Drug induced erythema multiforme: two case series with review of literature.
        J Clin Diagn Res. 2014; 8: ZH01-ZH04
        • Joseph T.I.
        • Vargheese G.
        • George D.
        • et al.
        Drug induced oral erythema multiforme: a rare and less recognized variant of erythema multiforme.
        J Oral Maxillofac Pathol. 2012; 16: 145-148
        • Sokumbi O.
        • Wetter D.A.
        Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist.
        Int J Dermatol. 2012; 51: 889-902
        • Wetter D.A.
        • Davis M.D.P.
        Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007.
        J Am Acad Dermatol. 2010; 62: 45-53
        • Lee M.K.
        • Kwon W.J.
        • Cho E.B.
        • et al.
        Imatinib mesylate-induced erythema multiforme: recurrence after rechallenge with 200 mg/day imatinib.
        Ann Dermatol. 2015; 27: 641-643
        • Tan Z.H.
        • Thoon K.C.
        • Koh M.J.
        Case series of three infants with erythema multiforme following hepatitis B vaccination.
        Pediatr Neonatal. 2016; 57: 72-75
        • Samim F.
        • Auluck A.
        • Zed C.
        • et al.
        Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment.
        Dent Clin North Am. 2013; 57: 583-596
        • Scully C.
        • Bagan J.V.
        Adverse drug reactions in the orofacial region.
        Crit Rev Oral Biol Med. 2004; 15: 221-239
        • Kaur G.
        • Verhamme K.M.
        • Dieleman J.P.
        • et al.
        Association between calcium channel blockers and gingival hyperplasia.
        J Clin Periodontol. 2010; 37: 625-630
        • Bhatia V.
        • Mittal A.
        • Parida A.K.
        • et al.
        Amlodipine induced gingival hyperplasia: a rare entity.
        Int J Cardiol. 2007; 122: e23-e24
        • Salman A.
        • Tekin B.
        • Koca S.
        • et al.
        Another adverse effect of vemurafenib: gingival hyperplasia.
        J Dermatol. 2016; 43: 706-707
        • Mangold A.R.
        • Bryce A.
        • Sekulic A.
        Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
        J Am Acad Dermatol. 2014; 71: e205-e206
        • Aral C.A.
        • Dilber E.
        • Aral K.
        • et al.
        Management of cyclosporine and nifedipine-induced gingival hyperplasia.
        J Clin Diagn Res. 2015; 9: ZD12-ZD15
        • Dongari-Bagtzoglou A.
        • Research, Science and Therapy Committee
        • American Academy of Periodontology
        Drug-associated gingival enlargement.
        J Periodontol. 2004; 75: 1424-1431
        • Ramalho V.L.
        • Ramalho H.J.
        • Cipullo J.P.
        • et al.
        Comparison of azithromycin and oral hygiene program in the treatment of cyclosporine-induced gingival hyperplasia.
        Ren Fail. 2007; 29: 265-270
        • Conde S.A.
        • Aarestrup F.M.
        • Vieira B.J.
        • et al.
        Roxithromycin reduces cyclosporine-induced gingival hyperplasia in renal transplant patients.
        Transplant Proc. 2008; 40: 1435-1438
        • Mutlu G.M.
        • Mutlu E.A.
        • Bellmeyer A.
        • et al.
        Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy.
        Am J Med. 2006; 119: 639-646
        • Feldmann M.
        • Charles P.
        • Taylor P.
        • et al.
        Biological insights from clinical trials with anti-TNF therapy.
        Springer Semin Immunopathol. 1998; 20: 211-228
        • Geale K.
        • Henriksson M.
        • Schmitt-Egenolf M.
        Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics.
        Br J Dermatol. 2016; 174: 579-587
        • Romero-Jimenez R.M.
        • Escudero-Vilaplana V.
        • Baniandres Rodriguez O.
        • et al.
        Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol.
        J Dermatolog Treat. 2016; 27: 198-202
        • Mease P.J.
        Do biologic-treated psoriatic arthritis patients with spondylitis respond differently with or without concomitant methotrexate from patients without spondylitis?.
        J Rheumatol. 2016; 43: 471-473
        • Hagen J.W.
        • Magro C.M.
        • Crowson A.N.
        Emerging adverse cutaneous drug reactions.
        Dermatol Clin. 2012; 30 (vii): 695-730
        • Flendrie M.
        • Vissers W.H.
        • Creemers M.C.
        • et al.
        Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.
        Arthritis Res Ther. 2005; 7: R666-R676
        • Moen K.
        • Kvalvik A.G.
        • Hellem S.
        • et al.
        The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: a pilot study.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100: 433-440
        • Corazza M.
        • Zauli S.
        • Ricci M.
        • et al.
        Does anti-tumour necrosis factor-alpha increase oral candida colonization? A case–control study in psoriatic patients.
        Acta Derm Venereol. 2013; 93: 352-353
        • Kaur N.
        • Mahl T.C.
        Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease.
        Dig Dis Sci. 2004; 49: 1458-1460
        • Bongartz T.
        • Sutton A.J.
        • Sweeting M.J.
        • et al.
        Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
        JAMA. 2006; 295: 2275-2285
        • Raaschou P.
        • Simard J.F.
        • Neovius M.
        • et al.
        • Anti-Rheumatic Therapy in Sweden Study Group
        Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
        Arthritis Rheum. 2011; 63: 1812-1822
        • Mariette X.
        • Matucci-Cerinic M.
        • Pavelka K.
        • et al.
        Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.
        Ann Rheum Dis. 2011; 70: 1895-1904
        • Rahman N.
        • Healy C.
        • Flint S.R.
        • et al.
        Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening.
        J Clin Rheumatol. 2010; 16: 197-199
        • Chainani-Wu N.
        • Chang C.
        • Gross A.J.
        • et al.
        Oropharyngeal carcinoma arising after methotrexate and etanercept therapy for rheumatoid arthritis.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 117: e261-e263
        • Leao J.C.
        • Duarte A.
        • Gueiros L.A.
        • et al.
        Severe oral epithelial dysplasia in a patient receiving adalimumab therapy.
        J Oral Pathol Med. 2005; 34: 447-448
        • Boussemart L.
        • Jacobelli S.
        • Batteux F.
        • et al.
        Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports.
        Dermatology. 2010; 221: 201-205
        • De Simone C.
        • Caldarola G.
        • D'Agostino M.
        • et al.
        Lichenoid reaction induced by adalimumab.
        J Eur Acad Dermatol Venereol. 2008; 22: 626-627